TEVA Prices $4.9 Billion of Senior Notes to Refinance Costlier Debt
Teva priced five tranches of euro- and dollar-denominated senior notes at coupons of 4.25% to 5.75% and will use the proceeds to redeem bonds carrying up to 8.125%.
Teva priced five tranches of euro- and dollar-denominated senior notes at coupons of 4.25% to 5.75% and will use the proceeds to redeem bonds carrying up to 8.125%.
Tadaa Technology will supply the AI backbone for a 1,000-acre solar farm feeding a data centre under a 25-year power arrangement, targeting $7.3M in annual revenue.
Alpha Compute has signed definitive agreements for Utica and Marcellus acreage with more than 75 wells, and plans to build a data center on the site.
Palisade Bio can start the Phase 2 ASCENTRA-CD trial of its oral PDE4 prodrug, with first dosing targeted for Q1 2027 and a primary readout in Q1 2028.
VERSATILE-002 results for PDS0101 plus pembrolizumab show 39.3 months median overall survival in checkpoint-inhibitor-naive HPV16-positive head and neck cancer.